A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of newly diagnosed or Recurrent Breast Carcinoma in frail or elderly patients.
This trial phase represents an early or specialized stage of clinical development.
Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.
Alpha Tau Medical Ltd. (DRTS) is the sponsoring company for this trial. BiotechSign currently grades this company F (26/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.